Quotes are at least 15-min delayed:2025/09/14 14:17 EDT
Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.66 
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
68.11/54.78
|
|
Enterprise Value
20.13B
|
| Balance Sheet |
|
Book Value Per Share
4.78
|
| Cash Flow |
|
Cash Flow Yield
0.05
|
| Income Statement |
|
Total Revenue
189.72B
|
|
Operating Revenue Per Share
3.85
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed：2025/09/14 14:17 EDT
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries. |
